T1	intervention 64 77	pegfilgrastim
T2	condition 100 119	febrile neutropenia
T3	eligibility 123 195	breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
T4	total-participants 709 712	351
T5	intervention-participants 720 723	177
T6	control-participants 755 758	174
T7	control 766 773	placebo
T8	age 781 804	between 20 and 69 years
T9	total-participants 1018 1021	346
T10	intervention-participants 1084 1087	173
T11	control-participants 1105 1108	173
T12	outcome 1115 1130	incidence of FN
T13	iv-bin-percent 1209 1212	1.2
T14	cv-bin-percent 1217 1223	68.8 %
T15	outcome 1314 1352	hospitalization and antibiotics for FN
T16	outcome 1359 1373	adverse events
